구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TK-deletion plus GM-CSF (JX-594: Recombinant vaccinia virus, JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)) Green Cross Corporation·Carcinoma, Hepatocellular 14 trials |
|---|---|
Overview Program | JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF) |
Overview Company | Green Cross Corporation |
Overview Modality | CGT |
Overview Target | Carcinoma, Hepatocellular |
Overview Indication | Carcinoma, Hepatocellular |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Using Computer Modeling and Experimental Methods to Screen for Aptamers That Bind to the VV-GMCSF-LACT Virus.. Oncolytic virotherapy is a promising approach for cancer treatment. However, when introduced into the body, the virus provokes the production of virus-neutralizing antibodies, which can reduce its antitumor effect. To shield viruses from the immune system, aptamers that can cover the memb… |
Clinical Safety signal | Using Computer Modeling and Experimental Methods to Screen for Aptamers That Bind to the VV-GMCSF-LACT Virus.. Oncolytic virotherapy is a promising approach for cancer treatment. However, when introduced into the body, the virus provokes the production of virus-neutralizing antibodies, which can reduce its antitumor effect. To shield viruses from the immune system, aptamers that can cover the memb… |
Clinical Selected reported efficacy | ORR 19.2% |
Clinical Reported ORR | 19.2% |
Clinical Result source | ClinicalTrials.gov NCT02562755 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02562755 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TK-deletion plus GM-CSF (JX-594: Recombinant vaccinia virus, JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)) Green Cross Corporation·Carcinoma, Hepatocellular 14 trials |
|---|---|
Overview Program | JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF) |
Overview Company | Green Cross Corporation |
Overview Modality | CGT |
Overview Target | Carcinoma, Hepatocellular |
Overview Indication | Carcinoma, Hepatocellular |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Using Computer Modeling and Experimental Methods to Screen for Aptamers That Bind to the VV-GMCSF-LACT Virus.. Oncolytic virotherapy is a promising approach for cancer treatment. However, when introduced into the body, the virus provokes the production of virus-neutralizing antibodies, which can reduce its antitumor effect. To shield viruses from the immune system, aptamers that can cover the memb… |
Clinical Safety signal | Using Computer Modeling and Experimental Methods to Screen for Aptamers That Bind to the VV-GMCSF-LACT Virus.. Oncolytic virotherapy is a promising approach for cancer treatment. However, when introduced into the body, the virus provokes the production of virus-neutralizing antibodies, which can reduce its antitumor effect. To shield viruses from the immune system, aptamers that can cover the memb… |
Clinical Selected reported efficacy | ORR 19.2% |
Clinical Reported ORR | 19.2% |
Clinical Result source | ClinicalTrials.gov NCT02562755 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02562755 |
추천 비교
추천 비교